19.9 C
New York

GLP-1 Effect: Eli Lilly and Company (LLY) Smashes Q3 2023 Revenue Expectations on Weight Loss Drug Tailwind


Eli Lilly and Company GLP-1 Earnings

The GLP-1 mania is in full swing now, as evidenced by Eli Lilly and Company (NYSE: LLY) smashing consensus expectations for its top-line and bottom-line metrics in Q3 2023, aided by the soaring demand for its Mounjaro weight loss drug. Eli Lilly and Company (NYSE: LLY) Earnings Release for the Third Quarter of 2023 For […]

Read full article at https://wccftech.com/glp-1-effect-eli-lilly-and-company-lly-smashes-q3-2023-revenue-expectations-on-weight-loss-drug-tailwind/

WccftechContinue reading/original-link]

Related articles


Recent articles